13 results about "Bipolar mood disorder" patented technology

This invention discloses a method for isolating and extracting *Havnia vesicularis* using penicillin and vancomycin. The method mainly includes the following steps: inclusion and screening of patients with bipolar disorder; collection and processing of feces from these patients; isolation and treatment of *Havnia vesicularis* by adding penicillin and vancomycin to the feces; and identification of *Havnia vesicularis*. This invention improves the isolation efficiency and success rate of *Havnia vesicularis*, solving the problems of low isolation efficiency and poor identification accuracy in existing technologies.

The application provides a model training method and a bipolar disorder personalized treatment dialogue generation method and device, belonging to the technical field of deep learning, aiming at the problems that the current diagnosis accuracy of bipolar mood disorder is not high and the matching of treatment dialogue with patients is poor, the model training can be performed on a multi-modal language model according to a voice signal with significant characteristics of bipolar mood disorder, and a target classification model for bipolar mood disorder classification is obtained. Since the voice signal contains characteristics such as semantics, tone, pronunciation rhythm and other characteristics directly related to bipolar mood disorder expressed by the patient, the target classification model can be used for accurate classification of bipolar mood disorder, and when the target classification model is used for classification of bipolar mood disorder, the excessive dependence on the subjective diagnosis of doctors can be avoided, and the accuracy of the classification prediction of bipolar mood disorder is effectively improved.

This invention discloses a method for identifying unipolar and bipolar depression based on deep learning-based multi-state EEG fusion, comprising: Step 1, performing continuous wavelet transform on EEG signals in open and closed states respectively to obtain open-eye time-frequency maps and closed-eye time-frequency maps; Step 2, using a deep learning model to extract features from the open-eye and closed-eye time-frequency maps obtained in Step 1 to obtain feature vectors for open-eye and closed-eye states; then, fusing the feature vectors in open-eye and closed-eye states to obtain a multi-state fused feature vector; finally, using a deep learning classification network to classify and identify the multi-state fused feature vector to obtain the identification result, thus completing the identification. This invention uses a deep learning model based on EEG signals to perform three-class classification identification of unipolar depression, bipolar disorder, and healthy individuals, improving classification performance.

There is provided bacterial compositions for treatment of bipolar disorder or symptoms thereof and methods of treating bipolar disorders or symptoms there of using the same. The compositions comprise a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.

This document describes a combination composition of compound 1 and fesoterodine for treating neurological disorders (e.g., schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive impairment in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia).

A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I):wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

The present invention relates to a diazaheterocyclic derivative of a pyridoaryl group having Kappa receptor antagonistic activity. Specifically, the present invention relates to a compound represented by general formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable salt of the stereoisomer. The present invention further relates to a pharmaceutical composition containing the compound and a preparation method therefor, a method for treating diseases related to Kappa receptor antagonistic activity, such as depression, depression with anhedonia, bipolar disorder, anxiety, and other mental diseases, and a use. The definition of each substituent in general formula (I) is the same as that in the description.

The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.

The application provides a pharmaceutical composition for preventing and treating senile cognitive impairment with bipolar disorder, a preparation method and application thereof, and belongs to the technical field of medicines.The pharmaceutical composition prepared by mixing volatile oil separated from Acorus calamus and Ligusticum chuanxiong and water extract separated from Acorus calamus, Ligusticum chuanxiong, Astragalus and Polygala is rich in volatile oil and various water-soluble active ingredients.Based on the characteristics of promoting nerve cell growth and memory impairment repair of the pharmaceutical composition, the application also provides application of the pharmaceutical composition in preparation of medicines for preventing and / or treating senile cognitive impairment and / or bipolar disorder.

Pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) antagonist / inhibitor are described for use in methods of treating, ameliorating or preventing mood disorders / affective disorders and / or chronic stress and / or anxiety disorders and / or Parkinson's disease. Furthermore, pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) agonist / activator are described for use in methods of treating, ameliorating or preventing bipolar disorder manic (ICD-10 F31), appetite disorders, preferably anorexia or bulimia. Furthermore, a method of assessing the activity of a candidate molecule suspected to be a NPBWR1 antagonist / inhibitor or agonist / activator is described.